Precision Biosciences Stock Investor Sentiment
| DTIL Stock | USD 7.24 0.02 0.28% |
About 68% of Precision BioSciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Precision BioSciences suggests that many traders are alarmed. Precision BioSciences' investing sentiment shows overall attitude of investors towards Precision BioSciences.
Precision |
Precision BioSciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Precision BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Precision BioSciences that are available to investors today. That information is available publicly through Precision media outlets and privately through word of mouth or via Precision internal channels. However, regardless of the origin, that massive amount of Precision data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Precision BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Precision BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Precision BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Precision BioSciences alpha.
Precision BioSciences Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Precision BioSciences Receives 13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal | 09/03/2024 |
2 | Disposition of 154 shares by Smith J. Jefferson of Precision BioSciences at 10.32 subject to Rule 16b-3 | 09/18/2024 |
3 | Wall Street SWOT Precision BioSciences stock navigates gene editing frontier - Investing.com | 09/27/2024 |
4 | Cartesian Therapeutics, Inc. Moves 26.9 percent Higher Will This Strength Last | 10/04/2024 |
5 | Precision BioSciences to Present at the European Society of Gene Cell Therapy 31st Annual Congress | 10/16/2024 |
6 | Precision BioSciences, Inc. Short Interest Down 7.1 percent in September | 10/18/2024 |
7 | Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B | 10/24/2024 |
8 | Precision BioSciences to Report Third Quarter Results on November 4, 2024 | 10/29/2024 |
9 | Disposition of 9443 shares by Michael Amoroso of Precision BioSciences subject to Rule 16b-3 | 11/01/2024 |
10 | Precision BioSciences Q3 Earnings Snapshot | 11/04/2024 |
11 | What is HC Wainwrights Estimate for DTIL FY2024 Earnings | 11/07/2024 |
12 | Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B | 11/15/2024 |
13 | Insider Buying John Kelly Acquires Shares of Precision BioSciences Inc | 11/22/2024 |
Check out Precision BioSciences Hype Analysis, Precision BioSciences Correlation and Precision BioSciences Performance. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.4 | Revenue Per Share 12.872 | Quarterly Revenue Growth (0.96) | Return On Assets (0.06) | Return On Equity 0.2444 |
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.